Introduction
Cervical cancer, which is one of the most common cancers, remains the leading cause of cancer deaths among females worldwide [1] . Approximately one-third of patients who present with invasive cervical cancer will die from this disease. More than 85% of cervical cancer cases and deaths occur in developing countries, including China, where chemotherapy is used to treat recurrent cervical cancer [2] . In China, there are approximately 130,000 In prior research, we observed the highly frequent overexpression of the LAPTM4B protein in cervical carcinoma and noted that this overexpression was associated with LAPTM4B could be a valuable biological marker for cervical cancer. However, the roles of the LAPTM4B gene in cervical cancer and the molecular mechanisms through which this gene performs its functions remain unknown. Although LAPTM4B is known to be a candidate oncogene and/or a potential therapeutic target in various cancers, the questions of whether this gene has similar roles in cervical cancer and whether it is involved in cervical cancer tumorigenesis are of great interest. In the present study, we investigated these questions in cervical cancer cells in vitro.
Materials and Methods

Cell lines
Three human cervical cancer cell lines (SiHa, HeLa and CaSki cells) were obtained from the ATCC containing 10% fetal bovine serum (FBS).
Construction of expression plasmids and screening of target sites
Four precursor microRNA (pre-miRNA) sequences that target LAPTM4B (GenBank accession number: NM_018407.4) were designed using Invitrogen Block-iT RNAi Designer, an RNAi design software from Invitrogen Corporation. The pre-miRNA sequencing primers are presented in Fig. 1A . Double-stranded E. coli 2000 reagent (Invitrogen) was then used to transfect these plasmids into 293T cells in accordance with the Preparation and titering of LAPTM4B RNAi lentiviral particles recombinant lentiviral vector and lentiviral packaging mix were co-transfected into 293T cells. Lentivirus-
Construction of the LAPTM4B miRNA lentiviral vector and cell infection
The most effective LAPTM4B RNAi lentiviral vectors, as determined by qPCR and western blotting, The DNA sequencing results showed that the inserts were correct, and no mutant was found in the recombinants.
Minneapolis, Minnesota, USA), in accordance with the manufacturer's instructions. In particular, absorbance values at 450 nm were determined with a microplate reader. Standard curves relating concentrations to absorbance values were then plotted.
In vitro tube formation assay
The angiogenesis in vitro Biosciences) following the manufacturer's instructions. The tube formation assay is based on the ability of endothelial cells to form 3D capillary-like tubular structures when cultured on a gel of basement membrane supernatants from the knockdown (LAPTM4B-miR-3 cells), the blank control (the untreated Hela cells), and the negative control groups (the lenti-LAPTM4B-miR-neg cells), respectively. Human umbilical vein 4 cells) were placed on a layer of polymerized Matrigel and incubated at .
Statistical analysis
The data are expressed as means ± SD (standard deviation) where applicable. Statistical analyses of P< 0.05 was considered
Results
Expression of LAPTM4B in human cervical cancer cell lines
RT-PCR analyses were used to determine LAPTM4B expression levels in three different cervical cancer cell lines: CaSki, SiHa, and HeLa cells. These three cell lines exhibited differing levels of LAPTM4B expression, with the highest LAPTM4B expression observed in the HeLa cell line (Fig. 2) .
DNA sequencing results indicated that the inserts in the four pre-miRNA sequences that target LAPTM4B were correct (Fig. 1B, C) . The successful transient transfection of assays indicated that among the four recombinant plasmids, pcDNA-LAPTM4B-miR3 was vector was inserted into the lentiviral vector for LAPTM4B RNAi. The effects of LAPTM4B knockdown on HeLa cell cycle progression and apoptosis were to untreated cells. These data suggest that LAPTM4B knockdown promotes apoptosis in HeLa cells (Fig. 5C, D) .
The study results indicated that LAPTM4B knockdown may suppress HeLa cell migration in vitro (Fig. 5B) . Subsequently, the ability to invade Matrigel was assessed using a Transwell assay. Images of cells stained with crystal violet suggested that the knockdown of P combination, these data indicate that LAPTM4B is involved in the migration and invasion of cervical cancer cells.
Expression of tumor-associated proteins
Several proteins that perform primary functions in the invasion, migration and .The western 
Effects of LAPTM4B on the tube formation of endothelial cells
We assessed tube formation after LAPTM4B knockdown in HeLa cervical cancer cells. Tube numbers for each group were assessed under a light microscope. As expected, pivotal role in promoting angiogenesis.
Detection of VEGF expression in the culture supernatant of tumor cell lines by ELISA
lower in the knockdown group compared with untreated HeLa cells (the control group) and lenti-LAPTM4B-miR-neg cells (the negative control group) (Fig. 7C) . mor-associated proteins of Hela cells after knockdown of LAPTM4B determined by western blotting.
Fig. 7. LAPTM4B is involved in cervical cancer angiogenesis in vitro -
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Discussion LAPTM4B LAPTM family [17] . Studies have demonstrated that LAPTM4B is up regulated in many human cancers and may play roles in the disease progression of malignant cells and in multihave indicated that LAPTM4B gene polymorphisms may play an important role in genetic susceptibility to cervical cancer in the Chinese population [20] . However, the precise role of LAPTM4B in cervical cancer progression remains unknown.
To elucidate the biological functions of LAPTM4B in cervical cancer tumorigenesis, we chose to investigate these functions in HeLa cells through a loss-of-function study that cell apoptosis and inhibited tumor growth, migration and invasion, resulting in the altered expression of certain metastasis-and invasion-related genes. More importantly, the RNAimediated knockdown of LAPTM4B reduced angiogenesis in tumors in a tube formation assay. Our data suggest that LAPTM4B is a potential therapeutic target for cervical carcinoma effects.
Previous studies have demonstrated that LAPTM4B overexpression activates certain proto-oncogenes and thereby promotes malignancy. The metastasis of tumor cells is dependent on the degradation of the components of the extracellular matrix by MMPs, particularly MMP-2 and MMP-9 [21]. Other studies have revealed the existence of latent links between LAPTM4B and MMPs [22] . Our study yielded similar results. We observed that LAPTM4B down regulation resulted in reduced expression and activity levels for MMP-2 and MMP-9. Therefore, these results suggested a positive relationship between LAPTM4B Cyclin-dependent kinases (CDKs) participate in many cellular processes and play an important role in the regulation of the cell cycle and of transcription. Recently, CDK12
various genes, such as BRCA1, ATM, ATR, FANCI and FANCD2 [23] . Moreover, certain data sensitivity to cytostatics that promote DNA damage and the inhibition of DNA repair [23] . However, the precise contributions of CDK12 to tumor initiation and progression have not expression. These results indicated that LAPTM4B knockdown inhibits the aggressiveness of cervical cancer, possibly by regulating CDK12. Therefore, CDK12 involvement is implicated as an underlying mechanism of cancer development that is affected by an LAPTM4B blockade.
Angiogenesis is an important process in tumor progression [24, 25] . Hypoxia, which is a common characteristic of all rapidly growing solid malignancies, may trigger the activation of certain tumor-related signaling transduction pathways, such as the hypoxia-inducible factor-1 (HIF-1 is a transcription factor known to be associated with most and promotes tumorigenesis through angiogenesis [27, 28] . One of the HIF-1-responsive to be a key regulator in hypoxia-induced angiogenesis [30] . Tumor growth relies on new blood vessels. Tang et al. have reported that the LAPTM4B protein is closely associated with progression and micro vessel density in the context of non-small cell lung cancer, suggesting that LAPTM4B could play an important role in tumor angiogenesis [10] . However, the exact study, an LAPTM4B blockade may play a direct role in the degradation of HIF-1 and the 
